Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Matt Breese

Manager, Marketing at MMIT
Find me on:

Recent Posts

MMIT Reality Check on Migraine Prevention (Dec 2020)

Posted by Matt Breese on Dec 26, 2020

According to our recent payer coverage analysis for migraine prevention treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Breast Cancer HR+/HER2+ (Dec 2020)

Posted by Matt Breese on Dec 18, 2020

According to our recent payer coverage analysis for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) breast cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Nonmetastatic Prostate Cancer (Dec 2020)

Posted by Matt Breese on Dec 11, 2020

According to our recent payer coverage analysis for nonmetastatic prostate cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Ovarian Cancer (Dec 2020)

Posted by Matt Breese on Dec 4, 2020

According to our recent payer coverage analysis for ovarian cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo) (Nov 2020)

Posted by Matt Breese on Nov 27, 2020

According to our recent payer coverage analysis for type 2 Diabetes (DPP4 and Combo) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Multiple Myeloma (Nov 2020)

Posted by Matt Breese on Nov 20, 2020

According to our recent payer coverage analysis for multiple myeloma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Cystic Fibrosis (Nov 2020)

Posted by Matt Breese on Nov 13, 2020

According to our recent payer coverage analysis for cystic fibrosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Chronic Lymphocytic Leukemia (Nov 2020)

Posted by Matt Breese on Nov 6, 2020

According to our recent payer coverage analysis for chronic lymphocytic leukemia (CLL) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Hepatocellular Carcinoma (Oct 2020)

Posted by Matt Breese on Oct 30, 2020

According to our recent payer coverage analysis for hepatocellular carcinoma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Psoriasis (Oct 2020)

Posted by Matt Breese on Oct 23, 2020

According to our recent payer coverage analysis for psoriasis (PsO) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing